Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

Tony Mok, G. Lopes, Byoung Chul Cho, Dariusz M. Kowalski, Kazuo Kasahara, Yi‐Long Wu, Gilberto de Castro, H.Z. Turna, Răzvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, M. Catherine Pietanza, Bilal Piperdi, Roy S. Herbst